<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        75-11-87
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1987
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LOPRESOR 100MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METOPROLOL TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lopresor is &nbsp;used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; correct an irregular heartbeat, and to keep the heart beating regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; help to protect the heart after a heart attack</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat angina chest pain triggered by exercise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat overactivity of the thyroid gland as part of complementary treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat palpitations caused by nervous tension or anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent migraine (a type of headache)</p><p>How Lopresor works</p><p>Lopresor belong to a group of medicines called beta blockers. They reduce the blood pressure in your veins by widening blood vessels.</p><p>Monitoring during your treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from heart disorders, your doctor may perform blood tests and monitor your heart function.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from a high level of sugar in the blood (diabetes) your doctor may regularly check your blood sugar levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from an overactive thyroid gland, your doctor may regularly check your thyroid and heart functions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking or have recently taken other medicines, your doctor may perform some blood tests and monitor your heart function.</p><p>If you have any questions about how Lopresor works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lopresor will only be prescribed for you by a doctor. Follow all your doctor&rsquo;s instructions carefully, even if they differ from the general information contained in this leaflet.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> (hypersensitive) to metoprolol, to any of the other ingredients in Lopresor listed at the end of this leaflet, or to another beta blocker.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of a heart disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a very slow heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden and oppressive chest pain (sign of heart attack)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very poor blood circulation in your limbs (for example, very cold, pale hands or feet, or pain in your leg muscles when you walk)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusually low blood pressure, an untreated tumor of the adrenal glands (pheochromocytoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma, or history of breathing difficulties with wheezing or coughing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you suffer</strong> <strong>from</strong> a severe drop in blood pressure, dizziness, fast heart beat, rapid and shallow breathing, cold clammy skin (signs of a heart disorder named cardiogenic shock).</p><p>If any of these apply to you, tell your doctor without taking Lopresor</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take special care with Lopressor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar levels (diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or are at risk of<strong> </strong>serious allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain when at rest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor blood circulation in your limbs (for example, very cold, pale hands or feet, or pain in your leg muscles when you walk).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tumor of the adrenal glands (pheochromocytoma), in which case you would require an additional treatment to Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; overactive thyroid gland.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you undergo</strong> an operation where an anesthetic is used during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you suffer from:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory diseases such as asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe syndrome called oculomucocutaneous syndrome whose signs include severe conjunctivitis and skin rash and ear infection</p><p>If any of these apply to you, <strong>tell your doctor before you take</strong> Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice</strong> spontaneous bleeding or bruising during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice</strong> very slow heartbeat during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice </strong>yellow skin and eyes, nausea, loss of appetite, dark urine during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experience</strong> an irregular heartbeat during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experience</strong> breathlessness, difficulty breathing when lying down, swelling of the feet or legs during treatment with Lopresor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experience</strong> hallucinations during treatment with Lopresor</p><p>If you get any of these symptoms, <strong>tell your doctor straight away.</strong></p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking other medicines</p><p><strong>Tell your doctor or pharmacist</strong> <strong>or healthcare provider</strong> if you are taking or have recently taken any other medicines, including herbal and non-prescription medicines. Some other medicines may interact with Lopresor These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some other medicines used to treat high blood pressure (e.g. prazosin, clonidine, verapamil, monoamine oxidase inhibitors (MAO), diltiazem, hydralazine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some other medicines used to treat chest pain (e.g. nitroglycerin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some other medicines used to treat irregular heartbeat (e.g. amiodarone, propafenone, quinidine, disopyramide tocainide, procainamide, ajmaline amiodarone, flecainide, digitalis glycosides such as digoxin, lidocaine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anesthetics used during surgery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenaline or similar substances, which are found in some eye and nose drops, and in some cough medicines or remedies for the common cold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insulin, or medicines used to treat high level of sugar in the blood (diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to relieve pain or inflammation (non-steroidal anti-inflammatory drugs such as COX-2 inhibitors)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (e.g. rifampicin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antivirals (e.g. ritonavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antihistamines used to treat hay fever (e.g. diphenhydramine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some&nbsp; medicines used to treat malaria(e.g. hydroxychloroquine or quinidine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antipsychotic medicines (e.g. thioridazine, chlorpromazine, fluphenazine, haloperidol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antidepressants (e.g. fluoxetine, paroxetine, fluvoxamine, sertraline, clomipramine, desipramine or bupropion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antifungals (e.g. terbinafine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ergot alkaloids, a class of medicines used to prevent and treat migraine headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dipyridamole, a medicine used to reduce the risk of blot clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines that may cause a decrease in heart rate (e.g. fingolimod, a medicine used to treat multiple sclerosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines that may cause a decrease in blood pressure (e.g. aldesleukin, a medicine used to treat kidney cancer)</p><p>&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking Lopresor with food and drink</p><p>Lopresor should be swallowed whole with a glass of water.</p><p>Lopresor: If you are advised to take Lopresor either with or without food then you should continue taking Lopresor with the same schedule for the entire duration of treatment.</p><p>Children and adolescents</p><p>Lopresor is not recommended for use in children.</p><p>Older people (65 years or above)</p><p>Lopresor can be used by people over the age of 65.</p><p>If you are older than 65, you will be given the same dose as other adults unless your doctor reduces the doses.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and breast-feeding</p><p>Tell your doctor if you are pregnant.</p><p>Lopresor should not be used during pregnancy unless clearly necessary. Your doctor will discuss with you the potential risks of taking Lopresor during pregnancy.</p><p>If you are breast-feeding, ask your doctor for advice. Lopresor should be taken with caution while breast-feeding.</p><p>Females of child-bearing potential and male patients</p><p>Tell your doctor if you are planning to become pregnant.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Driving and using machines</p><p>If you experience dizziness, tiredness or blurred vision during your treatment with Lopresordo not drive, use machinery, or perform other tasks that need full attention. Drinking alcohol may increase tiredness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dosage.</p><p>How much Lopresor to take</p><p>Your doctor will tell you exactly how many tablets of Lopresor to take.High Blood Pressure:</p><p>In general, the daily dosage is 100 to 200 mg daily. Lopresor can be taken either once daily (in the morning), or divided into two separate doses (one in the morning and one in the evening).</p><p>When Lopresor is used to treat an overactive thyroid gland, the dose is generally 150 to 200 mg daily, given as three or four separate doses.</p><p>When Lopresor is used to treat an irregular heartbeat, the dose is generally 100 to 150 mg daily, given as two or three separate doses.</p><p>Angina:</p><p>The daily oral dose is 100 to 200 mg, given in 2 divided doses; if necessary, the daily dose can be increased up to 400 mg.</p><p>After a heart attack:</p><p>The oral maintenance dose is 200 mg daily, given in 2 divided doses. The treatment should be continued for at least 3 months.</p><p>To prevent migraine:</p><p>The daily oral dose is 100 mg, given as a single dose in the morning. If necessary, the daily dose can be increased to 200 mg, given in 2 divided doses (morning and evening).</p><p>Depending on how you respond to treatment, your doctor may suggest a higher or lower dose.</p><p>When and how to take Lopresor</p><p>Lopresor tablets should be swallowed whole with a glass of water.</p><p>The divitabs can be halved along the breaking line; the half-tablets should then be swallowed whole with a glass of water.</p><p>Your doctor will tell you when to take your tablets. Taking your tablets at the same time each day will help you to remember when to take them.</p><p>How long to take Lopresor</p><p>Continue taking Lopresor following your doctor&rsquo;s instructions.</p><p>Do not change the dose or stop the treatment without talking to your doctor. If you stop taking Lopresor suddenly, your condition may become worse. Your doctor may want you to reduce the dose gradually before stopping treatment altogether.</p><p>If you have questions about how long to take Lopresor for, talk to your doctor or your pharmacist or healthcare provider.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take Lopresor</p><p>If you forget to take a dose of Lopresor take the missed dose as soon as you remember it. However, if it is almost the time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take more Lopresor than you should</p><p>If you have accidentally taken too many tablets, <strong>talk to your doctor straight away</strong>. You may require medical attention.</p><p>Some of the effects of a Lopresor overdose are: an abnormally slow heartbeat or an irregular heartbeat; very low blood pressure; breathlessness; difficulty breathing when lying down; swelling of the feet; loss of consciousness; nausea; vomiting; blue discoloration of the lips, tongue, skin; seizures; sudden and oppressive chest pain; and death.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you stop taking Lopresor</p><p>Do not change the dose or stop taking Lopresor without asking your doctor for advice.&nbsp; If you stop taking Lopresor suddenly, your condition may become worse for a while. If it is necessary for you to stop treatment, your doctor will advise you how to do it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, you may experience some side effects during your treatment with Lopresor, although not everybody gets them.</p><p>Some side effects could be serious and may need medical attention</p><p><strong><em>Common</em></strong><em>: These side effects may affect between 1 and 10 in every 100 patients</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very slow heartbeat</p><p><strong><em>Rare</em></strong><em>: These side effects may affect between 1 and 10 in every 10,000 patients.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of heart disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numb or cold toes and fingers possible signs of Raynaud&#39;s syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat</p><p><strong><em>Very rare:</em></strong><em> These side effects may affect less than 1 in every 10,000 patients.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous bleeding or bruising may be signs of low blood platelet levels (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellow skin and eyes, nausea, loss of appetite, dark urine (sign of liver disorder), hepatitis, pain and abnormal curvature of the penis.</p><p>If you experience any of these, <strong>tell your doctor straight away</strong>.</p><p>Some side effects are common</p><p><em>These side effects may affect between 1 and 10 in every 100 patients.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, fainting while standing up (sign of orthostatic hypotension - sometimes with loss of consciousness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>Some side effects are rare</p><p><em>These side effects may affect between 1 and 10 in every 10,000 patients.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (in the form of itchy rash, thickened patches of red/silver skin: signs of psoriasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing with wheezing or coughing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of alertness, somnolence or insomnia (trouble in sleeping)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingling in the extremities signs of paresthesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>Some side effects are very rare.</p><p><em>These side effects may affect less than 1 in every 10,000 patients.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in personality</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;visual disturbance (e.g. blurred vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eyes, eye irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; noises (e.g. hissing) in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing disorders (e.g. reduced hearing or hearing loss) at doses exceeding those recommended.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gangrene in patients with pre-existing severe peripheral circulatory disorders (where narrowed arteries reduce blood flow to your limbs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny or stuffy nose, sneezing (signs of rhinitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of the skin to sun</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal excess sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thickened patches of red/silver skin (signs of psoriasis worsening)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain and stiffness (signs of arthritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sex drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in ability to achieve or maintain an erection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function test results</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower back pain, kidney disorder, increased blood pressure, blot clot (possible signs of a build-up of fibrous tissue in the retroperitoneal space containing the kidneys, aorta, renal tract and various other structures)</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>Other reported side effects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal triglycerides blood values</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal cholesterol blood values</p><p>If you notice any other side effects not mentioned in this leaflet, please inform your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date shown on the box.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protect from moisture and heat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original packaging.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The active substance</strong> of Lopresor is metoprolol tartrate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients are</strong>:</p><p><strong>50 mg</strong> <strong>tablets</strong>: Silica aerogel, cellulose, lactose, magnesium stearate, sodium carboxymethyl starch, hydroxypropyl methylcellulose, red iron oxide (E 172), polysorbate 80, talc, titanium dioxide (E 171).</p><p><strong>100 mg tablets</strong>: Silica aerogel, cellulose, magnesium stearate, sodium carboxymethyl starch, hydroxypropyl methylcellulose, glyceryl polyethylene glycol oxystearate, talc, titanium dioxide (E 171).</p><p>This information might differ in some countries</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lopresor is supplied as tablets.
Lopresor 50 mg tablets contain 50 mg metoprolol.
The 50 mg tablet is film-coated, scored, capsule-shaped, biconvex, pale red
Lopresor 100 mg tablets contain 100 mg metoprolol. 
The 100 mg tablet is film-coated, scored,  round-shaped, biconvex, white
This information might differ in some countries.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                by Novartis Pharmaceutical Company in 11/ 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ُستخدم عقار لوبريسور لعلاج الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصحيح عدم انتظام ضربات القلب، والحفاظ على انتظام معدل ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المساعدة على حماية القلب بعد التَّعرض لنوبة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج ارتفاع ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الذبحة الصدرية (ألم الصدر) الذي يحفزه التَّمرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج فرط نشاط الغدة الدَّرقية كجزء من العلاج المكمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الخفقان النَّاجم عن التَّوتر العصبي أو القلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الصداع النصفي (نوع من الصداع).</p><p dir="RTL">كيفية عمل عقار لوبريسور</p><p dir="RTL">ينتمي عقار لوبريسور إلى مجموعة من الأدوية تُسمى حاصرات بيتا. فهو يخفض ضغط الدَّم في الأوردة لديك عن طريق توسيع الأوعية الدَّموية.</p><p dir="RTL">المراقبة أثناء علاجك بعقار لوبريسور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات بالقلب، قد يقوم الطبيب بإجراء اختبارات الدَّم ومراقبة وظائف القلب لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع مستوى السُّكَّرِ في الدَّم (مرض السُّكَّرِي) فربما يفحص الطبيب مستوى السكر في الدَّم لديك بانتظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط نشاط الغدة الدَّرقية، فقد يفحص طبيبك الغدة الدَّرقية ووظائف القلب لديك بانتظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أيَّة أدوية أخرى، فقد يقوم طبيبك بإجراء بعض اختبارات الدَّم ومراقبة وظائف القلب لديك.</p><p dir="RTL">إذا كانت لديك أية أسئلة حول كيفية عمل عقار لوبريسور أو لماذا تم وصف هذا الدَّواء لك، فاستشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لن يتم وصف عقار لوبريسور لك إِلَّا من قِبَل طبيب. اتبع جميع تعليمات طبيبك بعناية، حتى إذا كانت تختلف عن المعلومات العامة الواردة في هذه النَّشرة.</p><p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع استعمال عقار لوبريسور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من الحساسية</strong> &quot;الحساسية المفرطة&quot; تجاه ميتوبرولول أو أيٍّ من مكونات عقار لوبريسور الأخرى المُدرَجة في نهاية هذه النَّشرة أو لأي حاصرات بيتا أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْرُ التَّنَفُّس، صعوبة التَّنفس عند الاستلقاء، تورم القدمين أو الساقين (علامات على اضطراب القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء شديد بضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مفاجئ وضاغط في الصدر (علامة على التَّعرض لنوبة قلبية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف شديد بالدَّورة الدَّموية بالأطراف لديك (على سبيل المثال: برودة أو شحوب شديد باليدين أو القدمين، أو ألم بعضلات الساق لديك عند المشي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض غير معتاد في ضغط الدَّم، ورم غير معالج بالغدد الكظرية (ورم القواتم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو أو تاريخ من الإصابة بصعوبة التنفس مع أزيز بالصدر أو السعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من</strong> هبوط شديد في ضغط الدَّم، دوخة، سرعة ضربات القلب، سرعة التَّنفس وقلة كمية الهواء، &nbsp;برودة وتندي الجلد بالعرق (علامات على اضطراب قلبي يُسمى الصدمة القلبية).</p><p dir="RTL">إذا انطبق عليك أي مما سبق، فأخبر طبيبك دون تناول عقار لوبريسور.</p><p dir="RTL">إذا كنت تعتقد أنك قد تكون لديك حساسية، فاستشر طبيبك.</p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; الاحتياطات عند استعمال عقار لوبريسور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في الدَّم (مرض السُّكَّرِيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو كنت معرضًا لخطر الإصابة بتفاعلات حساسية خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر عند الرَّاحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف بالدَّورة الدَّموية بالأطراف لديك (على سبيل المثال: برودة أو شحوب شديد باليدين أو القدمين، أو ألم بعضلات الساق لديك عند المشي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم بالغدد الكظرية (ورم القواتم)، وفي تلك الحالة ستتطلب علاجًا إضافيًّا بجانب عقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدَّرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تخضع</strong> لعملية جراحية يتم فيها استخدام أدوية التَّخدير أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الجهاز التَّنفسي مثل الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة شديدة تُسمى المتلازمة العينية المخاطية الجلدية والتي تشمل علامات الإصابة بها التهاب المُلْتَحِمَة الشديد وطفحًا جلديًّا والإصابة بعدوى بالأذن.</p><p dir="RTL">إذا انطبق عليك أي مما سبق، <strong>فأخبر طبيبك قبل تناوُل عقار لوبريسور</strong><strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لاحظت</strong> وجود نزيف تلقائي أو كدمات أثناء العلاج بعقار لوبريسور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لاحظت</strong> انخفاضًا شديدًا في ضربات القلب أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لاحظت</strong> اصفرارًا بالجلد والعينين، الغثيان، فقدان الشهية، بولًا ذا لون داكن أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من </strong>عدم انتظام ضربات القلب أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تُعاني من</strong> عُسْر التَّنَفُّس، صعوبة التَّنفس عند الاستلقاء، تورم القدمين أو الساقين أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من </strong>هلوسة أثناء العلاج بعقار لوبريسور.</p><p dir="RTL">إذا أصبت بأيٍّ من هذه الأعراض،<strong> فأخبر طبيبك فورًا</strong><strong>.</strong></p><p dir="RTL">ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التداخلات الدوائية من أخذ عقار لوبريسور مع أدوية أخرى</p><p dir="RTL">أ<strong>خبر الطبيب أو الصيدلي الخاص بك أو مقدم الرعاية الصحية </strong>إذا كنت تتناول أو كنت قد تناولت مؤخرًا أيَّة أدوية أخرى، بما في ذلك الأدوية العشبية والأدوية التي حصلت عليها دون وصفة طبية. قد تتداخل بعض الأدوية الأخرى مع عقار لوبريسور، ويشمل ذلك الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية الأخرى التي تُستخدم في علاج ارتفاع ضغط الدَّم (على سبيل المثال: برازوسين، كلونيدين، فيراباميل، مثبطات أوكسيديز أحادي الأمين (مثبطات &quot;MAO&quot;)، ديلتِيازِيم، هيدرالازين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية الأخرى التي تُستخدم لعلاج ألم الصدر (على سبيل المثال: نِتْروجليسِرين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية الأخرى التي تُستخدم لعلاج عدم انتظام ضربات القلب (على سبيل المثال: أميودارون، بروبافينون، كينيدين، ديسوبيراميد توكاينيد، بروكايناميد، إجمالين أميودارون، فليكانيد، جليكوزيدات الديجيتالس مثل: ديجوكسِين، ليدوكائين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التَّخدير التي تُستخدم أثناء الجراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدرينالين أو المواد المشابهة، والتي توجد في بعض قطرات العين والأنف، وتوجد أيضًا في بعض أدوية علاج السعال أو أدوية علاج نزلات البرد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنسولين أو الأدوية التي تُستخدم في علاج ارتفاع مستوى السُّكَّرِ في الدَّم (مرض السُّكَّرِيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستخدم لتسكين الألم أو الالتهاب (مضادات الالتهاب غير الستيرويدية مثل مثبطات الأكسدة الحلقية-2).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية (على سبيل المثال: ريفامبيسين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الفيروسات (على سبيل المثال: ريتونافير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الهيستامين المستخدمة لعلاج حُمَّى القش (على سبيل المثال: دايفينهيدرامين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستخدم لعلاج الملاريا (على سبيل المثال: هيدروكسيكلوروكوين أو كينيدين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الذهان (على سبيل المثال: ثَيُوريدازين، كلُوربرُومازين، فلوفينازين، هالُوبِيرِيدُول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الاكتئاب (على سبيل المثال: فلوكسيتين، باروكسيتين، فلوفوكسامين، سيرترالين، كلوميبرامين، ديسيبرامين أو بُوبْرُوبْيُون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الفطريات (على سبيل المثال: تيربينافين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قَلَوانِيَّات الإرجوت، وهي فئة من الأدوية التي تُستخدم للوقاية من وعلاج حالات الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دايبيريدامول، وهو دواء يُستخدم للحد من خطر الجلطات الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي قد تسبب انخفاضًا في معدل ضربات القلب (مثل فينجوليمود، وهو دواء يستخدم لعلاج التصلب المتعدد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي قد تسبب انخفاضًا في ضغط الدم (مثل الديسلوكين ، وهو دواء يستخدم لعلاج سرطان الكلى)</p><p dir="RTL">د&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول عقار لوبريسور مع الطعام والشراب</p><p dir="RTL">يجب بلع أقراص عقار لوبريسور كاملة مع كوب من الماء.</p><p dir="RTL">عقار لوبريسور: إذا تم نصحك بتناول عقار لوبريسور سواء مع الطعام أو بدونه، فيجب عليك مواصلة تناول عقار لوبريسور بنفس الجدول الزَّمني طوال مدة العلاج بالكامل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا يُوصى باستخدام عقار لوبريسور في الأطفال.</p><p dir="RTL">المرضى من كبار السن (البالغون من العمر 65 عامًا فأكثر)</p><p dir="RTL">من الممكن استخدام عقار لوبريسور من قبل الأشخاص الذين تزيد أعمارهم عن 65 عامًا.</p><p dir="RTL">إذا كنت بعمر يزيد عن 65 عامًا، فسيتم إعطاؤك الجرعة نفسها التي يتم إعطاؤها للبالغين الآخرين ما لم يقم طبيبك بخفض الجرعات.</p><p dir="RTL">هـ. الحمل والرضاعة</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ &nbsp;حاملا.</p><p dir="RTL">يجب عدم استخدام عقار لوبريسور أثناء فترة الحمل ما لم يكن ذلك ضروريًّا بشكل واضح. سيناقش معكِ طبيبكِ الخطر المُحتمل الذي قد ينتج عن تناوُل عقار لوبريسور أثناء الحمل.</p><p dir="RTL">يُرجى استشارة طبيبك، إذا كنتِ مرضعًا. يجب تناول عقار لوبريسور بحذر أثناء الرضاعة الطبيعيَّة.</p><p dir="RTL">الإناث ممن لديهن القدرة على الحمل والمرضى من الذكور</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ حاملًا أو تنوين الحمل.</p><p dir="RTL">و&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثير عقار لوبريسور على القيادة واستخدام الآلات</p><p dir="RTL">إذا كنت تعاني من دوخة، أو تعب، أو عدم وضوح الرؤية أثناء علاجك بعقار لوبريسور، فلا تمارس القيادة أو تستخدم الآلات أو تقوم بإجراء المهام الأخرى التي تحتاج إلى انتباه كامل. قد يزيد تناول الكحوليات من الشعور بالتَّعب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُرجى اتباع تعليمات طبيبك بعناية. لا تتجاوز الجرعة الموصى بها.</p><p dir="RTL">ما كمية عقار لوبريسور التي يجب استخدامها؟</p><p dir="RTL">سيخبرك طبيبك بالضبط كم عدد الأقراص التي ستتناولها من عقار لوبريسور.</p><p dir="RTL">ارتفاع ضغط الدم:</p><p dir="RTL">بصفة عامة، تكون الجرعة اليومية هي 100 إلى 200 مجم يوميًّا. من الممكن تناول جرعة عقار لوبريسور إما مرَّة واحدة يوميًّا (صباحًا)، أو مقسمة على جرعتين منفصلتين (واحدة في الصباح وواحدة في المساء).</p><p dir="RTL">عند استخدام عقار لوبريسور لعلاج فرط نشاط الغدَّة الدَّرقية، تكون الجرعة بصفة عامة 150 إلى 200 مجم يوميًّا، ويتم إعطاؤها في هيئة ثلاث أو أربع جرعات منفصلة.</p><p dir="RTL">عند استخدام عقار لوبريسور لعلاج عدم انتظام ضربات القلب، تكون الجرعة بصفة عامة 100 إلى 150 مجم يوميًّا، ويتم إعطاؤها في هيئة جرعتين أو ثلاث جرعات منفصلة.</p><p dir="RTL">ذبحة صدرية:</p><p dir="RTL">تكون الجرعة اليومية هي 100 إلى 200 مجم، مقسمة على جرعتين منفصلتين، من الممكن رفع الجرعة اليومية إلى&nbsp; مجم400 عند الضرورة.</p><p dir="RTL">بعد نوبة قلبية:</p><p dir="RTL">الجرعة المستمرة هي 200 مجم يوميًا، مقسمة على جرعتين منفصلتين، يجب أن يستمر العلاج لمدة 3 أشهر على الأقل.</p><p dir="RTL">لمنع الصداع النصفي:</p><p dir="RTL">تكون الجرعة اليومية هي 100 مجم، تعطى مرة واحدة في الصباح. من الممكن رفع الجرعة اليومية إلى&nbsp; مجم200 عند الضرورة، مقسمة على جرعتين منفصلتين (في الصباح والمساء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك جرعة أعلى أو أقل، وفقًا إلى كيفية استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">متى وكيف تتناوَل عقار لوبريسور؟</p><p dir="RTL">يجب بلع أقراص عقار لوبريسور<strong> </strong>كاملة مع كوب من الماء.</p><p dir="RTL">من الممكن تقسيم الأقراص القابلة للانقسام إلى النصف من خلال خط الانكسار ؛ بعد ذلك يجب ابتلاع أنصاف الأقراص كاملة مع كوب من الماء.</p><p dir="RTL">وسيخبرك طبيبك بالوقت الذي يجب عليك فيه تناول الأقراص. تناوُل أقراصك في الوقت نفسه من كل يوم سيُساعدك على تذكُّر موعد تناوُلها.</p><p dir="RTL">المدة اللازمة لتناول عقار لوبريسور</p><p dir="RTL">يُرجى مواصلة تناوُل عقار لوبريسور مع اتباعا لتعليمات طبيبك.</p><p dir="RTL">لا تغير الجرعة أو توقف العلاج دون التَّحدث إلى طبيبك. إذا توقفت عن تناول عقار لوبريسور بشكل مفاجيء، فقد تسوء حالتك.&nbsp; قد يرغب طبيبك في خفض الجرعة تدريجيًّا قبل إيقاف العلاج تمامًا.</p><p dir="RTL">إذا كانت لديك أية استفسارات حول طول المدة اللازمة لتناول عقار لوبريسور، فيُرجى استشارة الطبيب أو الصيدلي الخاص بك أو مقدم الرعاية الصحية.</p><p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسيان تناول جرعة من عقار لوبريسور</p><p dir="RTL">إذا أغفلت تناول جرعة من عقار لوبريسور، فتناول الجرعة التي أغفلتها بمجرد تذكُّرها.&nbsp; ومع ذلك، إذا كان هذا الوقت هو وقت الجرعة التَّالية تقريبًا، فاترك الجرعة التي أغفلتها وعاود الاستمرار في جدول جرعاتك المُعتاد. لا تتناول جرعة مضاعفة.</p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الزائدة من عقار لوبريسور</p><p dir="RTL">إذا كنت قد تناولت كمية كبيرة جدًّا من الأقراص بطريق الخطأ، <strong>فتحدَّث إلى طبيبك على الفور.</strong> فقد تحتاج إلى الرعاية الطبية.</p><p dir="RTL">تشمل بعض تأثيرات الجرعة الزَّائدة من عقار لوبريسور ما يلي: بطء ضربات القلب بشكل غير طبيعي أو عدم انتظام ضربات القلب، انخفاضًا شديدًا في ضغط الدَّم، عُسْر التَّنَفُّس، صعوبة التَّنفس عند الاستلقاء، تورم القدمين، فقدان الوعي، الغثيان، القيء، تغير لون الشفتين أو اللسان أو الجلد إلى اللون الأزرق، نوبات تشنجية، ألم مفاجئ وضاغط في الصدر، والوفاة.</p><p dir="RTL">ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوقف عن تناول عقار لوبريسور</p><p dir="RTL">لا تغير الجرعة أو تتوقف عن تناول عقار لوبريسور دون طلب المشورة من طبيبك.&nbsp; إذا توقفت عن تناول عقار لوبريسور بشكل مفاجيء، فقد تسوء حالتك لبعض الوقت. وإذا كان من الضَّروري لك إيقاف العلاج، فسينصحك طبيبك بكيفية فعل ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، قد تعاني من بعض الآثار الجانبية أثناء علاجك بعقار لوبريسور، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">بعض الآثار الجانبية قد تكون خطيرة وقد تحتاج إلى عناية طبية</p><p dir="RTL"><strong><em>شائعة:</em></strong><em> قد تُؤثر هذه الآثار الجانبية في ما بين ١ و ١٠ في كل ١٠٠ مريض.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء شديد بضربات القلب.</p><p dir="RTL"><strong><em>نادرة:</em></strong><em> قد تُؤثر هذه الآثار الجانبية في ما بين ١ و ١٠ في كل ١٠٠٠٠ مريض</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس، صعوبة التَّنفس عند الاستلقاء، تورم القدمين أو الساقين (علامات على اضطرابات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل أو برودة أصابع القدمين وأصابع اليدين، علامات محتملة تشير لمتلازمة رينود.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL"><strong><em>نادرة جدًّا:</em></strong><em> قد تُؤثر هذه الآثار الجانبية على أقل من 1 في كل 10,000 مريض</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون النزيف التِّلقائي أو الكدمات علامات على انخفاض مستويات الصفائح الدَّموية (نقص الصَّفائح الدَّموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بالجلد والعينين، غثيان، فقدان الشهية، بول ذو لون داكن (علامة على اضطراب الكبد)، التهاب الكبد، ألم وانحناء غير طبيعي للعضو الذكري.</p><p dir="RTL"><strong>أخبر طبيبك فورًا</strong> إذا عانيت من أيٍّ من هذه الآثار.</p><p dir="RTL">بعض الآثار الجانبية تكون شائعة</p><p dir="RTL"><em>قد تُؤثر هذه الآثار الجانبية في ما بين ١ و ١٠ في كل ١٠٠ مريض.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، إغماء عند الوقوف (علامة على انخفاض ضغط الدَّم الانتصابي -أحيانًا مع فقدان الوعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق.</p><p dir="RTL">إذا كان أيٌّ من هذه الآثار يُؤثر عليك بشدة، <strong>فأخبر طبيبك.</strong></p><p dir="RTL">بعض الآثار الجانبية تكون نادرة</p><p dir="RTL"><em>قد تُؤثر هذه الآثار الجانبية في ما بين ١ و ١٠ في كل ١٠٠٠٠ مريض.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (في شكل طفح جلدي مصحوب بحكة، بقع سميكة بالجلد ذات لون أحمر/فضي: علامات على الصدفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التَّنفس مع أزيز بالصدر أو سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض اليقظة أو النَّيمومة أو الأرق (صعوبات النوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّنميل، وخز في الأطراف، علامات على اضطرابات بالإحساس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس.</p><p dir="RTL">إذا كان أيٌّ من هذه الآثار يُؤثر عليك بشدة، <strong>فأخبر طبيبك.</strong></p><p dir="RTL">بعض الآثار الجانبية تكون نادرة جدًّا.</p><p dir="RTL"><em>قد تُؤثر هذه الآثار الجانبية على أقل من 1 في كل 10,000 مريض</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في الشخصية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطرابات الرؤية (على سبيل المثال: عدم وضوح الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين، تهيُّج العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصوات (على سبيل المثال: هسهسة) في الأذن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالسمع (على سبيل المثال: قصور بالسمع أو فقدان السمع) عند جرعات تتجاوز الجرعات الموصى بها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غرغرينا في المرضى الذين يعانون من اضطرابات شديدة قائمة بالدَّورة الدَّموية الطرفية (حيث تقلل الشرايين التي بها تضيق من تدفق الدَّم إلى الأطراف لديك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف أو انسداد الأنف، عطس (علامات على الْتِهاب الأَنْف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفَم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد تجاه الشمس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التَّعرق بشكل غير طبيعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع سميكة ذات لون أحمر/ فضي على الجلد (علامات على تفاقم الصدفية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتصلب بالمفاصل (علامات على التهاب المفاصل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في الرَّغبة الجنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في القدرة على الوصول إلى الانتصاب أو المحافظة عليه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية باختبارات وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أسفل الظهر، اضطراب بالكلى، ارتفاع ضغط الدَّم، تخثر الدَّم (علامات محتملة على تراكم النسيج الليفي في التجويف الموجود خلف الصفاق والذي يحتوي على الكُلى، الأَبْهَر (الشريان الأورطي)، المسالك الكلوية والعديد من الأعضاء الأخرى).</p><p dir="RTL">إذا كان أيٌّ من هذه الآثار يُؤثر عليك بشدة، <strong>فأخبر طبيبك.</strong></p><p dir="RTL">الآثار الجانبية الأخرى التي تم الإبلاغ عنها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيم غير طبيعية للدهون الثلاثية بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيم غير طبيعية للكوليسترول بالدَّم.</p><p dir="RTL">إذا لاحظت أية آثار جانبية أخرى غير المذكورة في هذه النَّشرة، يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يستخدمه بعد انتهاء تاريخ الصلاحية الموضح على العبوة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيدًا عن الرطوبة والحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ داخل العبوة الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيدًا عن رؤية ومتناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعَّالة</strong> بعقار لوبريسور هي ميتوبرولول تارترات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى هي</strong><strong>:</strong></p><p dir="RTL"><strong>أقراص </strong><strong>50 مجم</strong>: إيروجل السيليكا، سليلوز، لاكتوز، ستيرات الماغنسيوم، نشا كاربوكسي ميثيل الصوديوم، هيدروكسي بروبيل ميثيل السليلوز، أكسيد الحديد الأحمر (E&nbsp;172)، بوليسوربات 80، تلك، ثاني أكسيد التيتانيوم (E 171).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص </strong><strong>100 مجم</strong><strong>:</strong> إيروجل السيليكا، سليلوز، ستيرات الماغنسيوم، نشا كاربوكسي ميثيل الصوديوم، هيدروكسي بروبيل ميثيل السليلوز، جليسيريل بولي إيثيلين الجلايكول أوكسي ستيرات،<em> </em>تلك، ثاني أكسيد التيتانيوم (E 171).</p><p dir="RTL">قد تختلف هذه المعلومات في بعض الدول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر عقار لوبريسور على هيئة أقراص</p><p dir="RTL">يحتوي لوبريسور 50 مجم أقراص على 50 مجم ميتوبرولول.</p><p dir="RTL">قرص 50 مجم عبارة عن قرص مغلف، محزز، على شكل كبسولة، ثنائي التحدُّب، ذو لون &nbsp;أحمر شاحب.</p><p dir="RTL">يحتوي لوبريسور 100 مجم أقراص على 100 مجم ميتوبرولول.</p><p dir="RTL">القرص بحجم 100 مجم عبارة عن قرص مغلف، محزز، على شكل &nbsp;كروي، ثنائي التحدُّب، ذو لون &nbsp;أبيض.</p><p dir="RTL">قد تختلف هذه المعلومات في بعض الدول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل شركة نوفارتس للأدوية في 11/ 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LOPRESOR® 50 mg and 100 mg, scored film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 50 mg, 100 mg metoprolol tartrate.
For a full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets of 50 mg: scored film-coated, capsule-shaped, biconvex
Tablets of 100 mg: scored film-coated, round shaped, biconvex.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cardiac tachyarrhythmia, including supraventricular<em> </em>and ventricular arrhythmias</p><p>Confirmed or suspected acute myocardial infarction, for secondary prevention after myocardial infarction</p><p>Hypertension: as monotherapy or for use in combination with other antihypertensives, for example, a diuretic, peripheral vasodilator or angiotensin converting-enzyme (ACE) inhibitor</p><p>Angina pectoris: For long-term prophylaxis Nitroglycerin should be used, if necessary, for alleviating acute attacks.</p><p>Hyperthyroidism (as adjunctive medication<em>)</em></p><p>Functional heart disorders with palpitation</p><p>Prevention of migraine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage regimen</p><p>General target population</p><p>The dosage should be adapted to the requirements of the individual patient. The following dosage recommendations may be taken as a guide:</p><p>Cardiac tachyarrhythmia</p><p><strong>Tablets</strong></p><p>The daily dose is 100 to 150 mg, given in 2 or 3 divided doses; if necessary, the daily dose can be increased to 300 mg</p><p><strong>Myocardial infarction</strong></p><p><strong>&nbsp;</strong></p><p><strong>a) Treatment in the acute stage </strong></p><p>The below recommended dosage can be reduced depending on the hemodynamic status of the patient.</p><p>Lopresor should be administered as soon as possible after the patient&#39;s arrival in hospital . Under constant hemodynamic monitoring (ECG, blood pressure, heart rate) one 5 mg bolus injection should be given intravenously, and repeated at 2 minute-intervals up to a total dose of 15 mg. Should any of the conditions listed under section 4.3 &ldquo;Contraindications&rdquo; arise, intravenous administration should be stopped immediately and appropriate measures instituted (see also section 4.9 &ldquo;Overdose&rdquo;). Provided the full intravenous dose (15 mg) has been tolerated well, oral therapy should be started 15 minutes later with 50 mg every 6 hours for 48 hours. For patients who do not tolerate the full intravenous dose, oral therapy should be initiated cautiously, starting with half the aforementioned oral dose.</p><p><strong>b) Maintenance treatment</strong></p><p>The oral maintenance dose is 200 mg daily, given in 2 divided doses. The treatment should be continued for at least 3 months.</p><p>Angina pectoris</p><p>The daily oral dose is 100 to 200 mg, given in 2 divided doses; if necessary, the daily dose can be increased up to 400 mg</p><p>Hyperthyroidism</p><p>The daily oral dose is 100 to 200 mg, given either as a single dose in the morning or as 2 divided doses (morning and evening). If necessary, another antihypertensive can be prescribed in addition (see section 4.1 &ldquo;therapeutic Indications&rdquo;).</p><p>Functional heart disorders with palpitation</p><p>The daily oral dose is 100 mg, given as a single dose in the morning. If necessary, the dose can be increased to 200 mg, given in 2 divided doses (morning and evening)</p><p>Prevention of migraine</p><p>The daily oral dose is 100 mg, given as a single dose in the morning. If necessary, the daily dose can be increased to 200 mg, given in 2 divided doses (morning and evening)</p><p>Special populations</p><p>Pediatric patients</p><p>No studies have been performed in pediatric patients. The safety and efficacy of Lopresor in pediatric patients have not been established</p><p><strong>Renal impairment</strong></p><p>No dosage regimen adjustment of Lopresor is required in patients with renal impairment</p><p><strong>Hepatic impairment</strong></p><p>Lopresor blood levels are likely to increase substantially in patients with hepatic impairment. Therefore, Lopresor should be initiated at low doses with cautious gradual dose titration according to clinical response</p><p><strong>Geriatric patients (&gt;65 years)</strong></p><p>No dosage regimen adjustment of Lopresor is required in geriatric patients but it should be given with caution due to increased likelihood of adverse events</p><p><strong>Method of administration</strong></p><p>For oral treatment, the tablets should be swallowed whole with a glass of water.</p><p>Lopresor should always be taken in standardized relation with meals. If the physician asks the patient to take Lopresor either before or with breakfast, then the patient should continue taking Lopresor with the same schedule over the course of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Known hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross-sensitivity between beta blockers can occur) 
•	Atrioventricular block of second or third degree 
•	Decompensated heart failure 
•	Clinically-relevant sinus bradycardia (heart rate less than 45 to 50 beats/min) 
•	Sick sinus syndrome 
•	Severe peripheral arterial circulatory disorders 
•	Cardiogenic shock 
•	Untreated pheochromocytoma (see section 4.4 “Special Warnings and precautions for use”) 
•	Hypotension 
•	For oral use: severe bronchial asthma or history of severe bronchospasm 
•	Patients with myocardial infarction who have a heart rate of less than 45 to 50 beats/min, P-R interval of greater than 0.24 sec, a systolic blood pressure of less than 100 mmHg, and/or severe heart failure 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bronchospastic diseases</p><p>In general, patients with bronchospastic diseases should not be given beta blockers, including Lopresor&nbsp; However, due to its relative cardioselectivity, oral Lopresor may be administered with caution to patients with mild or moderate bronchospastic diseases who do not respond to, or cannot tolerate, other suitable treatments Since beta<sub>1</sub>-selectivity is not absolute, a beta<sub>2</sub>-agonist should be administered concomitantly, and the lowest possible dose of Lopresor should be used</p><p>Diabetic patients</p><p>Lopresor should be used with caution in patients with diabetes mellitus, especially those who are receiving insulin or oral hypoglycemic agents (see section 4.5 &ldquo;Interactions&rdquo;). Diabetic patients should be warned that beta blockers, including Lopresor, may mask the tachycardia occurring with hypoglycemia. However, other manifestations of hypoglycemia such as dizziness and sweating may not be significantly suppressed, and sweating may be increased</p><p>Cardiovascular system</p><p>Beta blockers, including Lopresor, should not be used in patients with untreated congestive heart failure. This condition should first be stabilized</p><p>Due to their negative effect on atrioventricular conduction, beta blockers, including Lopresor, should be only given with caution to patients with first-degree atrioventricular block.</p><p>If the patient develops increasing bradycardia (heart rate less than 50 to 55 beats/min), the dosage should be gradually reduced or treatment gradually stopped.</p><p>Myocardial infarction</p><p>If significant hypotension occurs in patients with myocardial infarction, Lopresor should be discontinued, and the hemodynamic status of the patient and the extent of myocardial ischemia carefully assessed. Intensive hemodynamic monitoring may be required and appropriate treatment modalities should be instituted. If hypotension is associated with significant bradycardia or atrioventricular block, treatment should be directed at reversing these.</p><p>Peripheral circulatory disorders</p><p>Lopresor should be used with caution in patients with peripheral arterial circulatory disorders (for example, Raynaud&#39;s disease or phenomenon, intermittent claudication), because beta blocker treatment may aggravate such conditions.</p><p>Pheochromocytoma</p><p>In patients with known or suspected pheochromocytoma, Lopresor should always be given in combination with an alpha blocker and only after the alpha blocker has been initiated.</p><p>Anesthesia and surgery</p><p>Chronically administered beta blocker therapy should not be routinely stopped prior to major surgery. The impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. If a patient treated with Lopresor needs general anesthesia, the anesthetist should be informed that the patient is receiving a beta blocker. An anesthetic agent with as little cardiodepressant effect as possible should be used (see section 4.5 &ldquo;Interactions&rdquo;). If it is thought necessary to stop beta blocker therapy, including Lopresor, before surgery, this should be done gradually and completed approximately 48 hours before the general anesthetic</p><p>Abrupt discontinuation</p><p>Lopresor treatment should not be stopped suddenly, especially in patients with ischemic heart disease. To prevent exacerbation of angina pectoris, the dosage should be gradually reduced over 1 to 3 weeks and, if necessary, replacement therapy should be initiated at the same time</p><p>Anaphylactic reactions</p><p>Anaphylactic reactions precipitated by other agents may be particularly severe in patients taking beta blockers, and may be resistant to normal doses of adrenaline. Whenever possible, beta blockers, including Lopresor, should be avoided in patients who are at increased risk of anaphylaxis</p><p>Prinzmetal&#39;s angina</p><p>Beta blockers may increase the number and duration of angina attacks in patients with Prinzmetal&#39;s angina (variant angina pectoris). Relatively selective beta<sub>1</sub>-receptor blockers, such as Lopresor, can be used in such patients, but only with the utmost care</p><p>Thyrotoxicosis</p><p>Beta blockers mask some of the clinical signs of thyrotoxicosis. Therefore, when Lopresor is administered to patients having, or suspected of developing, thyrotoxicosis, both thyroid and cardiac function should be closely monitored</p><p>Oculomucocutaneous syndrome</p><p>The full oculomucocutaneous syndrome, has not been reported with Lopresor. However, part of this syndrome (dry eyes either alone or, occasionally, with skin rashes) has occurred. In most cases the symptoms cleared when Lopresor treatment was stopped. Patients should be observed carefully for potential ocular effects. If such effects occur, gradual discontinuation of Lopresor should be considered</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Calcium channel blockers (IV use)</strong></p><p>Calcium channel blockers such as verapamil and diltiazem may potentiate the depressant effects of beta blockers on blood pressure, heart rate, cardiac contractility and atrioventricular conduction. A calcium channel blocker of the verapamil (phenylalkylamine) type should not be given intravenously to patients receiving Lopresor because there is a risk of cardiac arrest in this situation (see section 4.4 &ldquo;Special Warnings and precautions for use&rdquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Interactions to be considered</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other antihypertensive drugs</strong></p><p>The effects of Lopresor and other antihypertensive drugs on blood pressure are usually additive<em>. </em>Patients receiving concurrent treatment with catecholamine depleting drugs, other beta blockers (including those in form of eye drops, such as timolol), or monoamine oxidase (MAO) inhibitors, should be carefully monitored. In addition, possibly significant hypertension may theoretically occur up to 14 days following discontinuation of the concomitant administration with an irreversible MAO inhibitor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calcium channel blockers (oral use)</strong></p><p>Co-administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility due to negative chronotropic and inotropic effects . Patients taking an oral calcium channel blocker of the verapamil type in combination with Lopresor should be closely monitored</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anti-arrhythmic drugs</strong></p><p>Beta-blockers may potentiate the negative inotropic effect of anti-arrhythmic agents and their effect on atrial-conduction time. Particularly, in patients with pre-existing sinus node dysfunction, co-administration of amiodarone may result in additive electro-physiologic effects including bradycardia, sinus arrest, and atrioventricular block anti-arrhythmic agents such as quinidine tocainide, procainamide, ajmaline amiodarone, flecainide and disopyramide may potentiate the effects of Lopresor on heart rate and atrioventricular conduction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nitroglycerin</strong></p><p>Nitroglycerin may enhance the hypotensive effect of Lopresor</p><p><strong>&nbsp;</strong></p><p><strong>Other drugs causing decrease in heart rate</strong></p><p>&nbsp;Concomitant administration of beta-blockers with other drugs known to decrease heart rate such as sphingosine-1-phosphate receptor modulators (e.g. fingolimod) may result in additive heart rate lowering effects.</p><p><strong>Other drugs causing decrease in blood pressure</strong></p><p>Concomitant administration of beta-blockers with other drugs known to decrease blood pressure such as aldesleukin may result in an enhanced hypotensive effect.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General anesthetics</strong></p><p>Some inhalation anesthetics may enhance the cardiodepressant effect of beta blockers (see section 4.4 &ldquo;Special Warnings and precautions for use&rdquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CYP2D6 inhibitors</strong></p><p>Potent inhibitors of this enzyme may increase the plasma concentration of metoprolol. Strong inhibition of CYP2D6 will result in the change of phenotype into poor metabolizer (see section 5 &ldquo;pharmacological properties&rdquo;). Caution should therefore be exercised when co-administering potent CYP2D6 inhibitors with metoprolol. Known clinically-significant potent inhibitors of CYP2D6 are antidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, desipramine antipsychotics such as chlorpromazine, fluphenazine, haloperidol, thioridazine, antiarrhythmics such as quinidine or propafenone, antiretrovirals such as ritonavir, antihistamines such as diphenhydramine, antimalarials such as hydroxychloroquine or quinidine, antifungals such as terbinafine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hydralazine</strong></p><p>Co-administration of hydralazine may inhibit pre-systemic metabolism of metoprolol leading to increased concentrations of metoprolol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digitalis glycosides</strong></p><p>Concomitant use of digitalis glycosides may result in excessive bradycardia and/or an increase in atrioventricular conduction time. Monitoring heart rate and PR interval is recommended</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sympathomimetics</strong></p><p>Co-administration of sympathomimetic drugs such as adrenaline, noradrenaline, isoprenaline, ephedrine, phenylephrine, phenylpropanolamine, and xanthine derivatives (including antitussives or nose and eye drops) with a beta blocker may enhance the pressor response</p><p>&nbsp;</p><p>resulting in hypertension due to mutual inhibition of therapeutic effects However, this is less likely with therapeutic doses of beta1-selective drugs than with non-selective beta-blockers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Non-steroidal&nbsp; anti-inflammatory drugs</strong></p><p>Co-administration of non-steroidal anti-inflammatory drugs including COX-2 inhibitors with a beta blocker may decrease the antihypertensive effect of metoprolol possibly as a result of the inhibition of renal prostaglandin synthesis and sodium and fluid retention caused by non- steroidal anti-inflammatory drugs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic enzyme inducers</strong></p><p>Enzyme-inducing drugs may affect plasma concentrations of metoprolol. For</p><p>example, the plasma concentration of metoprolol is lowered by rifampicin</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anti-adrenergic agents</strong></p><p>The antihypertensive effect of alpha-adrenergic blockers such as guanethidine, bethanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by beta blockers. Beta- adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the contrary, beta-adrenergic blockers may also potentiate the hypertensive response to discontinuation of clonidine in patients receiving concomitant clonidine and beta-adrenergic blockers If a patient is treated with clonidine and Lopresor concomitantly, and clonidine treatment is to be discontinued, Lopresor should be stopped several days before clonidine is discontinued</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antidiabetic drugs and insulin</strong></p><p>Beta blockers may interfere with the normal hemodynamic response to hypoglycemia and produce a rise in blood pressure associated with severe bradycardia In diabetic patients who use insulin, beta blocker treatment may be associated with increased or prolonged hypoglycemia. Beta blockers may also antagonise the hypoglycemic effects of sulfonylureas. The risk of either effect is less with a beta1-selective drug such as Lopresor than with a non-selective beta blocker. However, diabetic patients receiving Lopresor should be monitored to ensure that diabetic control is maintained (see section 4.4 &ldquo;Special Warnings and precautions for use&rdquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lidocaine (xylocaine)</strong></p><p>Metoprolol may reduce the clearance of lidocaine, leading to increased lidocaine effects</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Prazosin</strong></p><p>The acute postural hypotension that can follow the first dose of prazosin may be increased in patients already taking a beta-blocker, including Lopresor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ergot alkaloid</strong></p><p>Co-administration with beta blockers may enhance the vasoconstrictive action of ergot alkaloids</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dipyridamole</strong></p><p>In general, administration of a beta blocker should be withheld before dipyridamole testing, with careful monitoring of heart rate following the dipyridamole injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Alcohol</strong></p><p>Metoprolol may modify the pharmacokinetic parameters of alcohol</p><p><strong>Special populations </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment</strong></p><p>Metoprolol undergoes substantial hepatic first-pass metabolism, and is mainly eliminated by hepatic metabolism (see section 5 &ldquo;pharmacological properties&rdquo;). Therefore, hepatic impairment may increase the systemic bioavailability of metoprolol and reduce its total clearance, leading to increased plasma concentrations</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Geriatric patients</strong></p><p>Elderly patients should be treated cautiously. An excessive decrease in blood pressure or pulse rate may reduce the blood supply to vital organs to inadequate levels</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risk summary</strong></p><p>There is a limited amount of data on the use of metoprolol in pregnant women. Experience with metoprolol in the first trimester of pregnancy is limited, but no fetal malformations attributable to metoprolol have been reportedThe risk to the fetus/mother is unknown However, beta blockers may reduce placental perfusion Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of 50 mg/kg in rats and 25 mg/kg in rabbits, as demonstrated by increases in preimplantation loss</p><p>Lopresor should be given to pregnant women only if clearly needed The doctor should be immediately informed, if pregnancy is confirmed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Clinical&nbsp; Considerations</strong></p><p><strong>Disease-associated maternal and fetal risk</strong></p><p>Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post- partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dosage regimen adjustments during pregnancy and the postpartum period</strong></p><p>The pharmacokinetics of&nbsp; metoprolol is altered in pregnancy and the clearance is increased by 2-3 fold but no dose adjustment is required</p><p>In the case of treatment with Lopresor during pregnancy, the lowest possible dose should be used, and treatment discontinuation should be considered 2 to 3 days before delivery to avoid increased uterine contractility and effects of a beta-blockade in the newborn baby (for example, bradycardia, hypoglycemia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fetal/Neonatal adverse reactions</strong></p><p>Neonates of women with hypertension who are treated with beta-blockers during late pregnancy may be at increased risk for bradycardia and hypoglycemia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Animal Data</strong></p><p>Reproductive toxicity studies in mice, rats and rabbits did not show any teratogenic potential for metoprolol tartrate. Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of 50 mg/kg in rats and 25 mg/kg in rabbits, as demonstrated by increases in preimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the offspring <em>in utero</em>, which was reflected in minimally lower weights at birth</p><p><strong>Lactation</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;Risk summary</strong></p><p>Metoprolol is secreted into the breast milk: with therapeutic doses, an infant consuming 1 L of breast milk daily would receive a dose of less than 1 mg of metoprolol. Relative infant dose through breast milk is less than 1.0% of maternal weight-adjusted dose Nevertheless, breast-fed infants should be closely observed for signs of beta-blockade</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Females and males of reproductive potential Infertility</strong></p><p>The effects of Lopresor on human fertility have not been studied.</p><p>Metoprolol tartrate has been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of 3.5 mg/kg in rats (0.1 times the maximum human dose based on body surface area). However, no effect on reproductive performance was seen in male rats administered metoprolol tartrate at doses &ge;50 mg/kg (approximate to the maximum human dose)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dizziness, fatigue or visual impairment may occur during treatment with Lopresor (see section 4.8 &ldquo;Undesirable effects&rdquo;), and may adversely affect the patient&rsquo;s ability to drive or use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tabulated summary of adverse drug reactions from clinical trials<em> </em></p><p>Adverse drug reactions from clinical trials (Table 7-1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Toc308078816'><span style='mso-bookmark:_Toc308079105'><span
style='mso-bookmark:_Toc517874799'></span></span></span><span style='mso-element:
field-begin'></span><span style='mso-bookmark:_Toc308078816'><span
style='mso-bookmark:_Toc308079105'><span style='mso-bookmark:_Toc517874799'><span
style='mso-no-proof:yes'><span style='mso-spacerun:yes'> </span>STYLEREF
&quot;1&quot; \n<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span></span></span><![endif]-->7<!--[if supportFields]><span
style='mso-bookmark:_Toc308078816'><span style='mso-bookmark:_Toc308079105'><span
style='mso-bookmark:_Toc517874799'></span></span></span><span style='mso-element:
field-end'></span><![endif]-->-<!--[if supportFields]><span
style='mso-bookmark:_Toc308078816'><span style='mso-bookmark:_Toc308079105'><span
style='mso-bookmark:_Toc517874799'></span></span></span><span style='mso-element:
field-begin'></span><span style='mso-bookmark:_Toc308078816'><span
style='mso-bookmark:_Toc308079105'><span style='mso-bookmark:_Toc517874799'><span
style='mso-no-proof:yes'><span style='mso-spacerun:yes'>  </span>SEQ Table \s 1
\* ARABIC<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Toc308078816'><span style='mso-bookmark:_Toc308079105'><span
style='mso-bookmark:_Toc517874799'></span></span></span><span style='mso-element:
field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from clinical trials</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>thrombocytopenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>depression, nightmares</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>personality disorder, hallucinations</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>depressed level of consciousness, somnolence, insomnia, paraesthesia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>visual impairment(e.g. blurred vision), dry eyes, eye irritation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>tinnitus, hearing disorders<sup>1</sup> (e.g. hypoacusis or deafness)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>cardiac failure, arrhythmias, palpitation</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>conduction disorders, chest pain,</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>orthostatic hypotension (occasionally with syncope)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Oedema, Raynaud&#39;s phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>gangrene<sup>2</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>exertional dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>bronchospasm<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>rhinitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>nausea and vomiting, abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>diarrhoea or constipation</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>dry mouth, retroperitoneal fibrosis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>hepatitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>rash (in the form of urticaria, psoriasiform and dystrophic skin lesions)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>photosensitivity reaction, hyperhydrosis, alopecia, worsening of psoriasis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>arthritis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>erectile dysfunction, libido disorder ,Peyronie&#39;s disease</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>weight increase, liver function test abnormal</p></td></tr></tbody></table><p><sup>1</sup> in doses exceeding those recommended<sup>2</sup> in patients with pre-existing severe peripheral circulatory disorders</p><p><sup>3</sup> which may occur in patients without a history of obstructive lung disease</p><p>Adverse drug reactions from spontaneous reports and literature cases (frequency not known)</p><p>The following adverse reactions have been derived from post-marketing experience with Lopresor via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Toc266264819'><span style='mso-bookmark:_Toc266768478'><span
style='mso-bookmark:_Toc272145404'><span style='mso-bookmark:_Toc272145565'><span
style='mso-bookmark:_Toc287536162'><span style='mso-bookmark:_Toc308078817'><span
style='mso-bookmark:_Toc308079106'><span style='mso-bookmark:_Toc517874800'><span
style='mso-bookmark:_Toc260903681'></span></span></span></span></span></span></span></span></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:_Toc266264819'><span
style='mso-bookmark:_Toc266768478'><span style='mso-bookmark:_Toc272145404'><span
style='mso-bookmark:_Toc272145565'><span style='mso-bookmark:_Toc287536162'><span
style='mso-bookmark:_Toc308078817'><span style='mso-bookmark:_Toc308079106'><span
style='mso-bookmark:_Toc517874800'><span style='mso-bookmark:_Toc260903681'><span
style='mso-bidi-font-family:Arial'><span
style='mso-spacerun:yes'> </span>STYLEREF &quot;1&quot; \n<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span></span></span></span></span></span></span></span><![endif]-->7<!--[if supportFields]><span
style='mso-bookmark:_Toc266264819'><span style='mso-bookmark:_Toc266768478'><span
style='mso-bookmark:_Toc272145404'><span style='mso-bookmark:_Toc272145565'><span
style='mso-bookmark:_Toc287536162'><span style='mso-bookmark:_Toc308078817'><span
style='mso-bookmark:_Toc308079106'><span style='mso-bookmark:_Toc517874800'><span
style='mso-bookmark:_Toc260903681'></span></span></span></span></span></span></span></span></span><span
style='mso-element:field-end'></span><![endif]-->-2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from spontaneous reports and literature (frequency not known)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>confusional state</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>blood triglycerides increased, High Density Lipoprotein (HDL) decreased</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms</p><p>An overdosage of Lopresor may lead to severe hypotension, sinus bradycardia, atrioventricular block, myocardial infarction, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, loss of consciousness (or even coma), convulsions, nausea, vomiting, and cyanosis and death</p><p>Concomitant ingestion of alcohol, antihypertensives, quinidine, or barbiturates aggravates the signs and symptoms</p><p>The first manifestations of overdose appear 20 minutes to 2 hours after ingestion of Lopresor. The effects of massive overdose may persist for several days, despite declining plasma concentrations</p><p>Management</p><p>Patients should be admitted to hospital and, generally, should be managed in an intensive care setting, with continuous monitoring of cardiac function, blood gases, and blood biochemistry. Emergency supportive measures such as artificial ventilation or cardiac pacing should be instituted, if appropriate. Even healthy patients who have taken a small overdose should be closely observed for signs of poisoning for at least 4 hours</p><p>In the event of a potentially life-threatening oral overdose, vomiting or gastric lavage should be induced (if within 4 hours after ingestion of Lopresor) and/or activated charcoal should be used to remove the drug from the gastrointestinal tract Hemodialysis is unlikely to make a useful contribution to metoprolol elimination</p><p>Other clinical manifestations of overdose should be managed symptomatically based on modern methods of intensive care .Thebeta blocker withdrawal phenomenon (see section 4.4 &ldquo;Special Warnings and precautions for use&rdquo;) may occur after overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The stimulant effect of catecholamines on the heart is reduced or inhibited by metoprolol. This leads to a decrease in heart rate, cardiac contractility, and cardiac output</p><p>Metoprolol lowers elevated blood pressure in the standing and lying position. It also reduces the rise in blood pressure occurring in response to exercise. Treatment results in an initial increase in peripheral vascular resistance, which during long-term administration is normalized or, in some cases, reduced. As with all beta blockers, the precise mechanism of the antihypertensive effect of metoprolol is not fully understood. However, the long-term reduction in blood pressure with metoprolol appears to parallel this gradual decrease in total peripheral resistance.</p><p>In patients with angina pectoris, metoprolol reduces the frequency and severity of ischemic episodes and increases physical working capacity. These beneficial effects may be due to decreased myocardial oxygen demand as a result of the reduced heart rate and myocardial contractility.</p><p>In patients with supraventricular tachycardia, atrial fibrillation, or ventricular extrasystoles or other ventricular arrhythmias, metoprolol has a regulating effect on the heart rate. Its anti-arrhythmic action is primarily due to inhibition of the automaticity of pacemaker cells and to prolongation of atrioventricular conduction.</p><p>In patients with a suspected or confirmed myocardial infarction, metoprolol lowers mortality. This effect may possibly be attributable to a decrease in the incidence of severe ventricular arrhythmias, as well as to limitation of infarct size. Metoprolol has also been shown to reduce the incidence of non-fatal myocardial reinfarction</p><p>Through its beta-blocking effect, metoprolol is suitable for the treatment of functional heart disorders with palpitation, for the prevention of migraine, and add-on treatment for hyperthyroidism.</p><p>Long-term treatment with metoprolol may reduce insulin sensitivity. However, metoprolol interferes with insulin release and carbohydrate metabolism less than non-selective beta blockers.</p><p>In short-term studies, it has been shown that metoprolol may alter the blood lipid profile. It may cause an increase in triglycerides and a decrease in free fatty acids; in some cases, a small decrease in the high-density lipoprotein (HDL) fraction has been observed, although to a lesser extent than with non-selective beta blockers. In one long-term study lasting several years, cholesterol levels were found to be reduced. Pharmacokinetic and pharmacodynamic studies indicate that 30% of maximum beta-1-adrenoreceptor antagonistic activity is essential for minimum pharmacodynamic effect which is observed with about 45 nmol/L metoprolol in plasma</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following oral administration of conventional tablets, metoprolol is rapidly and almost completely absorbed from the gastrointestinal tract. The drug is absorbed evenly throughout the gastrointestinal tract. Absorption of metoprolol from Lopresor Retard tablets is slower, but the availability of metoprolol is similar compared with conventional tablets. Peak plasma concentrations are attained after approximately 1.5 to 2 hours with conventional metoprolol tablets, and after approximately 4 to 5 hours with sustained-release tablets. Plasma concentrations of metoprolol increase approximately in proportion with the dose in the 50 mg to 200 mg dose range. Owing to extensive hepatic first-pass metabolism, approximately 50% of a single oral dose of metoprolol reaches the systemic circulation. The extent of pre-systemic elimination differs between individuals because of genetic differences in oxidative metabolism. Although the plasma profiles exhibit wide inter-subject variability, they are reproducible within an individual Following repeated administration, the percentage of the dose systemically available is approximately 40% higher than after a single dose (that is, approximately 70%). This may be due to partial saturation of the first-pass metabolism, or reduced clearance as a result of reduced hepatic blood flow. Ingestion with food may increase the systemic availability of a single oral dose by approximately 20% to 40%</p><p>After intravenous injection, metoprolol is very rapidly distributed with a half-life of 5 to 15 min. Within the dose range of 10 to 20 mg, the plasma concentrations rise linearly in relation to the size of the dose. Metoprolol exhibits stereo-specific pharmacokinetics.</p><p><strong>Distribution</strong></p><p>Metoprolol is extensively and rapidly distributed, with a reported volume of distribution of 3.2 to 5.6 L/kg. The apparent volume of distribution at steady-state (Vss) in extensive metabolizers (4.84 L/kg) is relatively higher than poor metabolizers (2.83 L/kg). The half-life is not dose- dependent and does not change on repeated dosing. Approximately 10% of metoprolol in plasma is protein bound. Metoprolol crosses the placenta, and is found in breast milk. In patients with hypertension, metoprolol concentrations in cerebrospinal fluid are similar to those in plasma. Metoprolol is not a significant P-glycoprotein substrates indicating that inter-individual variability in pharmacokinetics of metoprolol can be majorly due to CYP2D6 metabolism</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Biotransformation / Metabolism</strong></p><p>Metoprolol is extensively metabolized by enzymes of the cytochrome P450 system in the liver. The main metabolic pathways of metoprolol are alpha-hydroxylation, O-demethylation, and oxidative deamination. Alpha-hydroxylation of metoprolol is stereo-selective. The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6).</p><p>However, the cytochrome P450 2D6 dependent metabolism of metoprolol seems to have little or no effect on safety or tolerability of the drug. None of the metabolites of metoprolol contribute significantly to its beta-blocking effect</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elimination</strong></p><p>The average elimination half-life of metoprolol is 3 to 4 hours; in poor metabolizers the half- life may be 7 to 9 hours. Following single oral administration of 100 mg metoprolol, the median clearances were 31, 168, and 367 L/h in poor metabolizers, extensive metabolizers, and ultra- rapid metabolizers, respectively. The renal clearance of the stereo-isomers does not exhibit stereo-selectivity in renal excretion. Approximately 95% of the dose can be recovered in urine. In most subjects (extensive metabolisers), less than 5% of an oral dose, and less than 10% of an intravenous dose, is excreted as unchanged drug. In poor metabolizers, up to 30% or 40% of oral or intravenous doses, respectively, may be excreted unchanged. The total plasma clearance of metoprolol after intravenous administration is approximately 1 L/min.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dose proportionality</strong></p><p>Metoprolol exhibits saturable pre-systemic metabolism leading to non-proportionate increase in the exposure with increased dose. However, a dose proportionate pharmacokinetics is expected with extended release formulations</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Food effect</strong></p><p>Food appeared to increase the rate of absorption of metoprolol leading to a slightly higher maximum plasma concentration at earlier time. However, it does not have a significant impact on the clearance or the time at which the maximum peak concentration is observed (Tmax).</p><p>In order to minimize the effect-variations within the individual, it is recommended that Lopresor should always be taken in standardized relation with food: If the physician asks the patient to take Lopresor either before or with breakfast then the patient should continue taking Lopresor with same dosing schedule during the course of therapy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Special populations</strong></p><p><strong>Geriatric patients (&gt;65 years or age or older)</strong></p><p>The geriatric population may show slightly higher plasma concentrations of metoprolol as a combined result of a decreased metabolism of the drug in elderly population and a decreased hepatic blood flow. However, this increase is not clinically-significant or therapeutically- relevant. Metoprolol does not meaningfully accumulate on repeated administration and there is no need to adjust the dose in elderly patients</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with renal impairment</strong></p><p>Pharmacokinetics of metoprolol is not impacted in patient with renal impairment. However, there is a possibility of accumulation of one of its less active metabolite in patients with a creatinine clearance below 5 mL/min and this accumulation would not influence the beta- blocking properties of metoprolol. Patients with renal impairment may usually be treated with normal doses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with hepatic impairment</strong></p><p>Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol. The elimination half-life of metoprolol is considerably prolonged, depending on severity (up to 7.2 h) in patients with liver impairment.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with a portacaval anastomosis</strong></p><p>Patients with a portacaval anastomosis had a systemic clearance of an intravenous dose of approximately 0.3 L/min and area under concentration-time curve (AUC) values up to 6-fold higher than those in healthy subjects</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with inflammatory disease</strong></p><p>Inflammatory disease has no effect on the pharmacokinetics of metoprolol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with hyperthyroidism</strong></p><p>Hyperthyroidism may increase the pre-systemic clearance of metoprolol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ethnic sensitivity</strong></p><p>The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolizer phenotype. Approximately 7% of Caucasians and less than 1% Orientals are poor metabolizers. CYP2D6 poor metabolizers exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolizer with normal CYP2D6 activity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Effect of gender</strong></p><p>There is no significant evidence to suggest a possible difference in elimination between the male and the female population, gender-specific recommendations for dosing of metoprolol are not necessary</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies</p><p>No additional clinical studies have been performed.</p><p>Non-clinical safety data</p><p>Reproductive toxicity</p><p>See section 4.6 &nbsp;Pregnancy, lactation and females and males of reproductive potential.</p><p>Mutagenicity</p><p>Metoprolol tartrate was devoid of mutagenic/genotoxic potential in the bacterial cell system (Ames) test and <em>in vivo</em> assays involving mammalian somatic cells or germinal cells of male mice</p><p>Carcinogenicity</p><p>Metoprolol tartrate was not carcinogenic in mice and rats after oral administration of doses up to 800 mg/kg for 21 to 24 months</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets of 50 mg: Silica aerogel, cellulose, lactose, magnesium stearate, sodium carboxymethyl starch, hydroxypropyl methylcellulose, red iron oxide (E 172), polysorbate 80, talc, titanium dioxide (E 171).</p><p>Tablets of 100 mg: Silica aerogel, cellulose, magnesium stearate, sodium carboxymethyl starch, hydroxypropyl methylcellulose, glyceryl polyethylene glycol oxystearate, talc, titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p><p>Protect from moisture and heat</p><p>must be kept out of the sight and reach of children.</p><p>Information might differ in some countries.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lopresor 50mg: blisters containing 40 tablets in PVC/PE/PVDC blisters<br />Lopresor 100mg: blisters containing 20 tablets in PVC/PE/PVDC blisters</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no specific instructions for use/handling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2019 by Novartis Pharmaceutical Company.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>